CollPlant outperforms Envoy Medical in small-cap medical company comparison, with higher revenue, earnings, and lower volatility.
CollPlant Biotechnologies (CLGN) outperforms Envoy Medical (COCH) in a comparison of small-cap medical companies, with higher revenue, earnings, and a lower beta. CollPlant has 21.7% institutional ownership and a beta of 0.24, suggesting 76% less volatility than the S&P 500. In contrast, Envoy Medical has 8.6% institutional ownership and a beta of 2.29, indicating 129% more volatility. CollPlant Biotechnologies has a consensus price target of $11.00, suggesting a potential upside of 152.29%, while Envoy Medical has a target of $7.25 and a potential upside of 220.80%. However, analysists believe Envoy Medical's higher upside potential makes it more favorable.
August 10, 2024
3 Articles